Genomics Market Will Generate Booming Growth Opportunities to 2032Posted by Ganesh Shinde on January 27th, 2023 According to Future Market Insights' recently published Genomics industry analysis report, global sales of Genomics will be valued at US$ 24.3 billion in 2021. From 2022 to 2032, the projected market growth rate is 19.8%, which is significantly higher than the historical rate. Functional Genomics is expected to generate the most revenue, with a CAGR of 23% between 2022 and 2032. According to Future Market Insights, a market research and competitive intelligence provider, the market value of the Genomics industry increased at a CAGR of around 16% from 2017 to 2021, with countries such as the United States, United Kingdom, China, South Korea, and Japan holding a significant share of the global market. As a result, the genomics market is expected to grow at a CAGR of 19.8% over the next ten years. Due to an increase in the number of research programmes, numerous strategic alliances, and a higher share of FDA approvals by the US FDA, the US dominated the global market with a share of more than 30% in 2021. Decisions on reimbursement and usage policies in this market may increase the adoption of genetic tests. Color Genomics, Inc., in collaboration with NorthShore University HealthSystem, implemented clinical genomics into routine care under the US health programme in January 2020. Furthermore, the company assisted Sanford in its Imagenetics genomics initiative to improve medical decision-making. Genomics Market: Segmentation Valuable information covered in the FMI’s Genomics market report has been segregated into key segments and sub-segments. By Application:
By Deliverable:
By End-use:
Browse More Details@ https://www.futuremarketinsights.com/reports/genomics-market Key players covered in the report include: Thermo Fisher Scientific, Agilent Technologies, Beijing Genomics Institute, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., GE Healthcare, Illumina Inc., Oxford Nanopore Technologies, QIAGEN N.V., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Eppendorf AG, and Eurofins Scientific Like it? Share it!More by this author |